Bausch + Lomb Corp.
11/13/2025 | Press release | Distributed by Public on 11/13/2025 06:25
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day (Form 8-K)
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
VAUGHAN, Ontario, Nov. 13, 2025 - Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at the New York Stock Exchange.
Leading Through Reinvention
Over the past few years, Bausch + Lomb has undergone a complete transformation by redefining how it operates. The company has sharpened its focus through simplification, rebuilt its culture around accountability and innovation and embraced AI and other new technologies to succeed now and well into the future.
"Bausch + Lomb today is a fundamentally different company than it was just a few years ago," said Brent Saunders, chairman and CEO, Bausch + Lomb. "We've reignited a sense of ownership and ambition across the organization to better serve patients, customers and consumers and deliver sustainable, profitable growth."
Three-Year Plan for Profitable Growth1
During the event, Bausch + Lomb leadership will unveil plans to achieve above-market revenue growth and meaningful margin expansion. The company's target of 5 - 7% constant currency revenue CAGR2 through 2028 is expected to be driven by holistic growth in its base business and recent product launches across the spectrum of eye health needs. The company's target of approximately 23% adjusted EBITDA (ex. Acq. IPR&D) margin2 in 2028 is expected to be fueled by continuous improvements to how it sources, makes and sells products, and an ongoing examination of opportunities to streamline internal processes. Bausch + Lomb will also announce additional financial targets of double-digit adjusted annual earnings per share growth (ex. Acq. IPR&D)2 from 2026 - 2028, approximately 50% adjusted cash flow from operations to adjusted EBITDA (ex. Acq. IPR&D) conversion2 in 2028 and net leverage2 of approximately 3.5x by the end of 2028.
The company will also reaffirm its 2025 guidance.
"Our roadmap to above-market growth and meaningful margin expansion is clear," said Sam Eldessouky, executive vice president and chief financial officer, Bausch + Lomb. "We're driving P&L leverage and making smart investments in innovation and execution to ensure that every dollar contributes to long-term value creation for our shareholders."
1 The financial targets and guidance in this news release are only effective as of the date given, November 13, 2025, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed financial targets or guidance. Distribution or reference of this news release following November 13, 2025, does not constitute the Company re-affirming these financial targets and guidance. See the "Forward-looking Statements" section for further information.
2 This is a non-GAAP measure or ratio. For further information on non-GAAP measures and ratios, please refer to the "Non-GAAP Information" section of this news release.
Loaded and Differentiated Pipeline
Most of the event will be dedicated to Bausch + Lomb's rebuilt product pipeline, with R&D and commercial leaders highlighting potential game-changing innovations at varying clinical stages in each business unit. Total projected peak sales of pipeline products, with anticipated peaks staggered based on launch dates, is approximately $7 billion.
"We're pushing the boundaries of ocular science to transform how eye diseases - from common to complex - are understood, treated and ultimately prevented," said Yehia Hashad, MD, executive vice president, R&D and chief medical officer, Bausch + Lomb. "We've been bringing new products to market at a record pace, and our innovation engine is built to sustain growth well into the next decade."
Pipeline products by business that will be highlighted:
Consumer
| · | New PreserVision® formulation - AREDS3 - would support vision health in people with age-related macular degeneration (AMD) through the addition of a proprietary vitamin B complex (anticipated launch: 1H 2026) |
| · | New formulation of LUMIFY® - the #1 eye doctor recommended redness reliever - combining brimonidine and hyaluronic acid would make for a more luxurious feeling drop with a fast onset of action (anticipated launch: 1H 2027) |
| · | Preservative-free lipid-based formulation of Blink® Triple Care (anticipated launch: 1H 2026) and new bottle technology under development would introduce additional science-backed OTC options for dry eye sufferers |
Pharmaceuticals
| · | Potential first-in-class dual-action eye drop combining the active ingredients of MIEBO® and XIIDRA® is expected to address both the evaporative and inflammatory causes of dry eye (anticipated launch: ~2029) |
| · | First neurosensory-targeted therapy for ocular surface pain - the #1 reason for visits to eye care professionals - would address a critical unmet need (anticipated launch: ~2030) |
| · | Glaucoma medication under development would be the first to treat vision loss in addition to lowering intraocular pressure (anticipated launch: ~2031) |
| · | Early-stage research collaborations designed to address unmet patient needs in intermediate AMD and geographic atrophy (anticipated launch dates: 2030+) |
Surgical
| · | enVista Beyond™ intraocular lens using pure refractive optics - no diffractive rings - expected to provide a continuous extended depth of focus and reduce dysphotopsias (anticipated launch: 2027) |
| · | ELIOS™ - already approved in Europe and backed by extensive clinical data - brings a truly implant-free minimally invasive glaucoma surgery approach, using excimer laser precision to create outflow channels safely and effectively (anticipated U.S. launch: 2H 2026) |
| · | SeeNova™, a new phaco and vitreoretinal platform, to offer enhanced fluidics and multi-function handpieces to make surgery more efficient (anticipated launch: 2028) |
| · | SeeLyra™, a next generation femtosecond laser, to feature live optical coherence tomography guidance and soft docking for accuracy and patient comfort (anticipated launch: 2H 2026) |
|
Page 2 |
Contact Lens
| · | There has not been a new contact lens material breakthrough in the industry for more than 25 years; that would change with the planned introduction of a bioactive hyaluronic acid hydrogel lens, creating an entirely new category (anticipated launch: 2028) |
| · | Cost-competitive daily disposable silicon hydrogel lens would provide eye care professionals with a new option for price-conscious patients (anticipated launch: 2029) |
| · | Premium silicon hydrogel offering would introduce a new level of comfort in the frequent replacement lens category (anticipated launch: 2029) |
| · | Silicon hydrogel lens designed to slow the progression of myopia in children and young adolescents would address a growing need that's becoming more and more urgent (anticipated launch: 2029) |
The investor day presentation, which details the three-year financial targets and delves into the science behind each pipeline product, and webcast registration details are available on the Investor Relations section of the Bausch + Lomb website.
###
About Bausch + Lomb
Our mission is simple - we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
Bausch + Lomb Corp. published this content on November 13, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 13, 2025 at 12:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]